SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jessica Liu, Hwai-I Yang, Chien-Jen Chen, Author's response: Hepatitis B virus seromarkers clearance and risk of hepatocellular carcinoma: serious risks of misinterpretation, Gut, 2015, 64, 1, 186.2

    CrossRef

  2. 2
    Vincent Wai-Sun Wong, Harry L.A. Janssen, Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?, Journal of Hepatology, 2015, 63, 3, 722

    CrossRef

  3. 3
    Yi-Chun Hung, Chih-Lin Lin, Chun-Jen Liu, Hung Hung, Shi-Ming Lin, Shou-Dong Lee, Pei-Jer Chen, Shu-Chun Chuang, Ming-Whei Yu, Development of risk scoring system for stratifying population for hepatocellular carcinoma screening, Hepatology, 2015, 61, 6
  4. 4
    Li-Shuai Qu, Jin-Xia Liu, Hai-Feng Zhang, Jing Zhu, Cui-Hua Lu, Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta-analysis, Hepatology Research, 2015, 45, 8
  5. 5
    Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka, Toshie Mashiba, Atsushi Hiraoka, Hironori Ochi, Yohei Koizumi, Fujimasa Tada, Masashi Hirooka, Osamu Yoshida, Yusuke Imai, Masanori Abe, Yoichi Hiasa, Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients, Hepatology International, 2015,

    CrossRef

  6. 6
    Pierre Nahon, Angela Sutton, Marianne Ziol, Jessica Zucman-Rossi, Jean-Claude Trinchet, Nathalie Ganne-Carrié, Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease, Hepatic Oncology, 2015, 2, 1, 63

    CrossRef

  7. 7
    Georgios K. Nikolopoulos, Dimitrios Paraskevis, Mina Psichogiou, Angelos Hatzakis, HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals, Journal of Medical Virology, 2015, 87, 10
  8. 8
    Véronique Loustaud-Ratti, Jérémie Jacques, Marilyne Debette-Gratien, Paul Carrier, Hepatitis B and elders: An underestimated issue, Hepatology Research, 2015, 45, 8
  9. 9
    Da-wu Zeng, Yue-yong Zhu, Qian Huang, Jie-min Zhang, Yin-lian Wu, Jing Dong, Jia-ji Jiang, Yu-rui Liu, Hepatitis B surface antigen in late hepatitis B infection, Journal of Medical Virology, 2015, 87, 3
  10. 10
    X-L Wei, M-Z Qiu, Y Jin, Y-X Huang, R-Y Wang, W-W Chen, D-S Wang, F Wang, H-Y Luo, D-S Zhang, F-H Wang, Y-H Li, R-H Xu, Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases, British Journal of Cancer, 2015, 112, 7, 1283

    CrossRef

  11. 11
    A. Suk-Fong Lok, Hepatitis B: 50 years after the discovery of Australia antigen, Journal of Viral Hepatitis, 2015, 22, 9
  12. 12
    Chien-Jen Chen, Mei-Hsuan Lee, Jessica Liu, Hwai-I Yang, Hepatocellular carcinoma risk scores: ready to use in 2015?, Hepatic Oncology, 2015, 2, 1, 1

    CrossRef

  13. 13
    T.-C. Tseng, C.-J. Liu, H.-C. Yang, C.-L. Chen, W.-T. Yang, C.-S. Tsai, S. F.-T. Kuo, F. C. Verbree, T.-H. Su, C.-C. Wang, C.-H. Liu, P.-J. Chen, D.-S. Chen, J.-H. Kao, Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers, Gut, 2015, 64, 2, 292

    CrossRef

  14. 14
    F. van Bömmel, T. Berg, Langzeittherapie der HBV-Infektion mit oralen Polymeraseinhibitoren, Der Gastroenterologe, 2015, 10, 4, 268

    CrossRef

  15. 15
    Jian Li, Juan Li, Yunwen Bao, Kunyi Pan, Xianghua Lin, Xiaoqiang Liu, Han Wang, Ying Xu, Xiaohong Luo, Hongyu Li, Chaohui Duan, Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma, Journal of Clinical Laboratory Analysis, 2015, 29, 4
  16. You have free access to this content16
    Nicolas Goossens, Yujin Hoshida, Personalized management of hepatocellular carcinoma based on molecular information: Future prospects, Clinical Liver Disease, 2015, 5, 6
  17. 17
    Anna S. Lok, Personalized treatment of hepatitis B, Clinical and Molecular Hepatology, 2015, 21, 1, 1

    CrossRef

  18. 18
    Chih-Lin Lin, Jia-Horng Kao, Perspectives and control of hepatitis B virus infection in Taiwan, Journal of the Formosan Medical Association, 2015,

    CrossRef

  19. 19
    J. Liu, T.-C. Tseng, H.-I. Yang, M.-H. Lee, R. Batrla-Utermann, C.-L. Jen, S.-N. Lu, L.-Y. Wang, S.-L. You, P.-J. Chen, C.-J. Chen, J.-H. Kao, Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System, Journal of Infectious Diseases, 2015, 211, 10, 1566

    CrossRef

  20. 20
    George V. Papatheodoridis, Henry Lik-Yuen Chan, Bettina E. Hansen, Harry L.A. Janssen, Pietro Lampertico, Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy, Journal of Hepatology, 2015, 62, 4, 956

    CrossRef

  21. 21
    J. L. Hou, Z. L. Gao, Q. Xie, J. M. Zhang, J. F. Sheng, J. Cheng, C. W. Chen, Q. Mao, W. Zhao, H. Ren, D. M. Tan, J. Q. Niu, S. J. Chen, C. Pan, H. Tang, H. Wang, Y. M. Mao, J. D. Jia, Q. Ning, M. Xu, S. M. Wu, J. Li, X. X. Zhang, Y. Ji, J. Dong, J. Li, Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial, Journal of Viral Hepatitis, 2015, 22, 2
  22. 22
    Qing Pang, Jing-Yao Zhang, Xin-Sen Xu, Si-Dong Song, Wei Chen, Yan-Yan Zhou, Run-Chen Miao, Kai Qu, Su-Shun Liu, Ya-Feng Dong, Chang Liu, The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma, Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 1, 73

    CrossRef

  23. 23
    Roongruedee Chaiteerakij, Benyam D. Addissie, Lewis R. Roberts, Update on Biomarkers of Hepatocellular Carcinoma, Clinical Gastroenterology and Hepatology, 2015, 13, 2, 237

    CrossRef

  24. 24
    Chih-Lin Lin, Tai-Chung Tseng, Jia-Horng Kao, What can we learn from hepatitis B virus clinical cohorts?, Liver International, 2015, 35,
  25. 25
    Jessica Liu, Hwai-I Yang, Mei-Hsuan Lee, Richard Batrla-Utermann, Chin-Lan Jen, Sheng-Nan Lu, Li-Yu Wang, San-Lin You, Chuhsing Kate Hsiao, Chien-Jen Chen, Distinct seromarkers predict different milestones of chronic hepatitis B progression, Hepatology, 2014, 60, 1
  26. You have free access to this content26
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, HBsAg quantification: useful for monitoring natural history and treatment outcome, Liver International, 2014, 34,
  27. 27
    Christian Trépo, Henry L Y Chan, Anna Lok, Hepatitis B virus infection, The Lancet, 2014, 384, 9959, 2053

    CrossRef

  28. 28
    Arige Tarhuni, Erwan Guyot, Pierre Rufat, Angela Sutton, Valérie Bourcier, Véronique Grando, Nathalie Ganne-Carrié, Marianne Ziol, Nathalie Charnaux, Michel Beaugrand, Richard Moreau, Jean-Claude Trinchet, Abdellah Mansouri, Pierre Nahon, Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis, Journal of Hepatology, 2014, 61, 2, 342

    CrossRef

  29. 29
    S. Davison, Management of chronic hepatitis B infection, Archives of Disease in Childhood, 2014, 99, 11, 1037

    CrossRef

  30. 30
    Guoyu Zhang, Na Li, Pingping Zhang, Fang Li, Cuiling Yang, Qianqian Zhu, Qunying Han, Yi Lv, Zhihua Zhou, Zhengwen Liu, PD-1 mRNA expression is associated with clinical and viral profile and PD1 3′-untranslated region polymorphism in patients with chronic HBV infection, Immunology Letters, 2014, 162, 1, 212

    CrossRef

  31. 31
    Yang Yang, Qi-Jun Wu, Li Xie, Wong-Ho Chow, Nat Rothman, Hong-Lan Li, Yu-Tang Gao, Wei Zheng, Xiao-Ou Shu, Yong-Bing Xiang, Prospective cohort studies of association between family history of liver cancer and risk of liver cancer, International Journal of Cancer, 2014, 135, 7
  32. 32
    Rong-Dang Fu, Chun-Hui Qiu, Hu-An Chen, Zhi-Gang Zhang, Min-Qiang Lu, Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma, Tumor Biology, 2014, 35, 8, 7603

    CrossRef

  33. 33
    Jia-Horng Kao, Risk stratification of HBV infection in Asia-Pacific region, Clinical and Molecular Hepatology, 2014, 20, 3, 223

    CrossRef

  34. 34
    J. Liu, H.-I. Yang, M.-H. Lee, S.-N. Lu, C.-L. Jen, R. Batrla-Utermann, L.-Y. Wang, S.-L. You, C. K. Hsiao, P.-J. Chen, C.-J. Chen, Y. Liaw, D. Chen, P. Chen, C. Hsieh, H. Lee, P. Yang, C. Chen, J. Chen, S. Huang, C. Jan, T. Chen, C. Sun, M. Wu, S. Chen, K. Chu, S. Ho, T. Lu, W. Wu, T. Ou, C. Lin, K. Shih, W. Chung, C. Li, C. Chen, W. How, Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma, Gut, 2014, 63, 10, 1648

    CrossRef

  35. 35
    Rama Kapoor, Shyam Kottilil, Strategies to eliminate HBV infection, Future Virology, 2014, 9, 6, 565

    CrossRef

  36. 36
    C. S. Coffin, M. Rezaeeaval, J. X. Pang, L. Alcantara, P. Klein, K. W. Burak, R. P. Myers, The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy, Alimentary Pharmacology & Therapeutics, 2014, 40, 11-12
  37. 37
    C. Höner zu Siederdissen, M.P. Manns, M. Cornberg, Was ist gesichert in der Therapie der chronischen Virushepatitis?, Der Internist, 2013, 54, 12, 1427

    CrossRef